Yesterday, the molecular diagnostic company issued preliminary results for its fourth quarter which exceeded analysts' estimates. Total income for the quarter is estimated to be between $ 294 million and $ 296 million, reflecting a top line beat of around $ 4 million to $ 6 million.
The better than expected result was that it received the Health Dynamic, which was completed in November and gave access to Oncotype DX gene generation tests used in treatment decisions. for more than 1 million cancer patients worldwide. During the quarter, the growth of Oncotype DX test volumes of 14%, or the total amount of the test of 41,000, helped to generate genetic income between $ 118 and $ 119 million, up 13% year on year.
vas) – em em em em em em em em em em em em em em em em em em em em em em em em em em colon cancer screening at home, income is likely to come within a range of $ 229 million to $ 230 million. This comes with the consensus estimate, BTIG analyzes. Amanda Murphy It reminds investors that the difference between consensus and guidance is the highest this year. It points out that the manager 's range of leads for the quarter had a "consensus on province' s income." If achieved, this figure represents a year – on – year increase of 61%. "Data-reactid =" 14 “On top of this, Cologuard, is likely to see the revenue, within a range of $ 229 million to $ 230 million, the colon colon cancer screening test, FDA which is approved by FDA. Amanda Murphy reminds the investor that the difference between agreement and guidance was the highest difference this year. She points out that “there was a consensus on the income of the Colleges at the end of management direction for the quarter.” T with a year-on-year increase of 61%.
Based on the expected College income, it is not surprising, then, that the amounts for the screening test are expected to be in line with the estimate. The results show that a Cologuard test size of 477,000 may be destined. This would not only lead to management above 465,000 to 475,000, but would also represent a significant growth of 63%.
While there is no 2020 directive offered by management before its call for earnings in February, Murphy notes that the results reiterate his already established bullish thesis. “Since Cologuard was sanctioned in 2014, Exact has achieved wide refund cover, developed a large sales force and experience, increased its laboratory capacity to seven million tests per year, and made significant investments in IT infrastructure. . We believe that Cologuard has an inflected point and expects the company to reach its long-term goal of 40% penetration on the market by the end of 2030, ”she explained. The four star analyst added, “Although not explicitly included in our current evaluation model, we are also optimistic about the potential for Exact liquid biopsy testing for liver cancer.” T
((0)) type sm em em em em em em em em em em em em em em em em em em em amh amh amh amh amh amh Remembering this, Murphy kept both of well with a $ 127 price target. This gives confidence in Exact ability to climb 40% higher in the next twelve months (To see Murphy's record, Click here) "With this in mind, Murphy kept both Purchasing ratings and a $ 127 price target. This brings his confidence in Exact capacity to climb 40% higher in the next twelve months. Click here)
</ p> (0) – Mt (0) – sm Mt (0.8em) – sm "type" text "content =" About the rest of the Street? Other analysts enthusiastically with BTIG analyzes, out of a total of 9 analyzes published in the last three months, 100% see the stock as Purchasing. .See the Precision Sciences stock analysis on TipRanks) "About the rest of the Street?" He says that other analysts agree enthusiastically with the BTIG analyst. For 9 full analyzes published in the last three months, see 100% This means that the consensus rate is a Strong Purchase Buyer Not to mention The target price is $ 123.56, it offers the potential over Murphy's forecast at 37%.